Display options
Cite
Coronel R, Jesus DM, Dalle Ore L, et al. Activation of Langerhans-Type Dendritic Cells Alters Human Cytomegalovirus Infection and Reactivation in a Stimulus-Dependent Manner. Front Microbiol. 2016;7:1445doi: 10.3389/fmicb.2016.01445.
Coronel, R., Jesus, D. M., Dalle Ore, L., Mymryk, J. S., & Hertel, L. (2016). Activation of Langerhans-Type Dendritic Cells Alters Human Cytomegalovirus Infection and Reactivation in a Stimulus-Dependent Manner. Frontiers in microbiology, 71445. https://doi.org/10.3389/fmicb.2016.01445
Coronel, Roxanne, et al. "Activation of Langerhans-Type Dendritic Cells Alters Human Cytomegalovirus Infection and Reactivation in a Stimulus-Dependent Manner." Frontiers in microbiology vol. 7 (2016): 1445. doi: https://doi.org/10.3389/fmicb.2016.01445
Coronel R, Jesus DM, Dalle Ore L, Mymryk JS, Hertel L. Activation of Langerhans-Type Dendritic Cells Alters Human Cytomegalovirus Infection and Reactivation in a Stimulus-Dependent Manner. Front Microbiol. 2016 Sep 14;7:1445. doi: 10.3389/fmicb.2016.01445. eCollection 2016. PMID: 27683575; PMCID: PMC5021960.
Copy Download .nbib Format: NLM
Share it on

Front Microbiol. 2016 Sep 14;7:1445. doi: 10.3389/fmicb.2016.01445. eCollection 2016.

Activation of Langerhans-Type Dendritic Cells Alters Human Cytomegalovirus Infection and Reactivation in a Stimulus-Dependent Manner.

Frontiers in microbiology

Roxanne Coronel, Desyree M Jesus, Lucia Dalle Ore, Joe S Mymryk, Laura Hertel

Affiliations

  1. Center for Immunobiology and Vaccine Development, Children's Hospital Oakland Research Institute Oakland, CA, USA.
  2. Department of Microbiology and Immunology and Department of Oncology, The University of Western Ontario London, ON, Canada.

PMID: 27683575 PMCID: PMC5021960 DOI: 10.3389/fmicb.2016.01445

Abstract

Oral mucosal Langerhans cells (LC) are likely to play important roles in host defense against infection by human cytomegalovirus (CMV). We previously showed that in vitro-differentiated immature LC (iLC) populations contain smaller amounts of infected cells but produce higher yields than mature LC (mLC) cultures, obtained by iLC stimulation with fetal bovine serum (FBS), CD40 ligand (CD40L) and lipopolysaccharide (LPS). Here, we sought to determine if exposure to select stimuli can improve LC permissiveness to infection, if specific components of the mLC cocktail are responsible for lowering viral yields, if this is due to defects in progeny production or release, and if these restrictions are also effective against reactivated virus. None of the stimuli tested extended the proportion of infected cells to 100%, suggesting that the block to infection onset cannot be fully removed. While CD40L and FBS exerted positive effects on viral progeny production per cell, stimulation with LPS alone or in combination with CD40L was detrimental. Reductions in viral titers were not due to defects in progeny release, and the permissive or restrictive intracellular environment established upon exposure to each stimulus appeared to act in a somewhat similar way toward lytic and latent infections.

Keywords: cytomegalovirus; dendritic cells; host defense; infection restrictions; langerhans cells

References

  1. J Gen Virol. 1993 Nov;74 ( Pt 11):2333-8 - PubMed
  2. Trends Mol Med. 2008 May;14(5):191-8 - PubMed
  3. J Gen Virol. 1996 Dec;77 ( Pt 12):3099-102 - PubMed
  4. J Oral Maxillofac Pathol. 2013 Sep;17(3):329-33 - PubMed
  5. Inflamm Res. 2006 Jul;55(7):293-9 - PubMed
  6. J Virol. 1989 Jul;63(7):3026-33 - PubMed
  7. J Gen Virol. 2010 Mar;91(Pt 3):599-604 - PubMed
  8. Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3932-7 - PubMed
  9. Clin Exp Immunol. 1999 Jan;115(1):153-60 - PubMed
  10. J Infect Dis. 1999 Feb;179(2):484-8 - PubMed
  11. Aust Dent J. 1995 Feb;40(1):46-9 - PubMed
  12. Oral Microbiol Immunol. 2006 Aug;21(4):256-60 - PubMed
  13. Allergy. 2008 Jun;63(6):720-7 - PubMed
  14. N Am J Med Sci. 2013 Sep;5(9):505-14 - PubMed
  15. J Gen Virol. 2005 Nov;86(Pt 11):2949-54 - PubMed
  16. Transpl Infect Dis. 1999 Sep;1(3):157-64 - PubMed
  17. J Virol. 2013 Oct;87(19):10660-7 - PubMed
  18. Br J Haematol. 2004 Aug;126(3):410-7 - PubMed
  19. Eur J Immunol. 2003 Jun;33(6):1528-38 - PubMed
  20. J Biol Chem. 2012 Aug 3;287(32):26702-14 - PubMed
  21. J Virol. 1994 Jun;68(6):4017-21 - PubMed
  22. Blood. 2004 Jun 1;103(11):4207-15 - PubMed
  23. J Virol. 2014 Jan;88(1):403-16 - PubMed
  24. J Virol. 2003 Jul;77(13):7563-74 - PubMed
  25. J Clin Periodontol. 1998 Dec;25(12):1003-7 - PubMed
  26. EMBO J. 1989 Dec 20;8(13):4251-8 - PubMed
  27. J Virol. 2012 Aug;86(16):8507-15 - PubMed
  28. Anat Cell Biol. 2015 Sep;48(3):177-87 - PubMed
  29. Transplantation. 1994 Sep 27;58(6):675-80 - PubMed
  30. J Virol. 2011 Dec;85(23):12750-8 - PubMed
  31. J Dent Res. 2006 Aug;85(8):678-89 - PubMed
  32. Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3937-42 - PubMed
  33. Proc Natl Acad Sci U S A. 2007 Nov 27;104(48):19061-6 - PubMed
  34. Anticancer Res. 2001 Jan-Feb;21(1A):113-7 - PubMed
  35. J Oral Pathol Med. 1994 Feb;23(2):55-9 - PubMed
  36. Exp Lung Res. 1998 Jan-Feb;24(1):3-14 - PubMed
  37. Nucleic Acids Res. 1992 Jul 11;20(13):3287-95 - PubMed
  38. Crit Rev Oral Biol Med. 1996;7(1):36-58 - PubMed
  39. Antiviral Res. 2011 Jun;90(3):151-9 - PubMed
  40. Proc Natl Acad Sci U S A. 2010 Nov 16;107(46):20039-44 - PubMed
  41. Virology. 1995 Apr 1;208(1):197-206 - PubMed
  42. Eur J Immunol. 1997 Dec;27(12):3135-42 - PubMed
  43. Allergy. 2006 Feb;61(2):166-72 - PubMed
  44. Blood. 1997 Sep 15;90(6):2482-91 - PubMed
  45. J Allergy Clin Immunol. 2003 Jul;112(1):141-8 - PubMed
  46. J Oral Pathol Med. 1989 Oct;18(9):510-6 - PubMed
  47. J Virol. 1999 Jun;73(6):4806-12 - PubMed
  48. Rev Med Virol. 2010 Nov;20(6):372-9 - PubMed
  49. J Virol. 2015 May;89(10):5615-32 - PubMed
  50. Proc Natl Acad Sci U S A. 2005 Mar 15;102(11):4140-5 - PubMed
  51. Mediators Inflamm. 1998;7(5):319-25 - PubMed
  52. Cell Death Differ. 2006 Apr;13(4):672-5 - PubMed

Publication Types

Grant support